Brighton Jones LLC bought a new stake in shares of Celgene Corporation (NASDAQ:CELG) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 7,555 shares of the biopharmaceutical company’s stock, valued at approximately $940,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in CELG. Meridian Wealth Management LLC bought a new position in shares of Celgene Corporation during the first quarter valued at about $780,000. Hutchens Investment Management Inc boosted its position in shares of Celgene Corporation by 5.7% in the first quarter. Hutchens Investment Management Inc now owns 19,985 shares of the biopharmaceutical company’s stock valued at $2,486,000 after buying an additional 1,085 shares during the last quarter. Green Square Capital LLC boosted its position in shares of Celgene Corporation by 0.6% in the first quarter. Green Square Capital LLC now owns 12,779 shares of the biopharmaceutical company’s stock valued at $1,590,000 after buying an additional 77 shares during the last quarter. Ashford Capital Management Inc. bought a new position in shares of Celgene Corporation during the first quarter valued at about $546,000. Finally, Horizon Investment Services LLC bought a new position in shares of Celgene Corporation during the first quarter valued at about $3,207,000. 78.34% of the stock is currently owned by institutional investors.

Shares of Celgene Corporation (CELG) traded up 1.42% during trading on Monday, reaching $132.47. The company’s stock had a trading volume of 653,015 shares. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $139.00. The company has a 50 day moving average of $134.14 and a 200 day moving average of $124.30. The company has a market cap of $103.64 billion, a PE ratio of 41.03 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the previous year, the firm posted $1.44 earnings per share. The business’s revenue was up 18.7% compared to the same quarter last year. On average, analysts anticipate that Celgene Corporation will post $7.32 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Brighton Jones LLC Takes Position in Celgene Corporation (CELG)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/14/brighton-jones-llc-takes-position-in-celgene-corporation-celg.html.

Several research firms have weighed in on CELG. Vetr raised Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective on the stock in a research report on Thursday. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $175.00 price objective on shares of Celgene Corporation in a research report on Wednesday, August 9th. Cann reissued a “buy” rating and issued a $175.00 price objective on shares of Celgene Corporation in a research report on Tuesday, August 1st. Jefferies Group LLC reissued a “buy” rating and issued a $160.00 price objective on shares of Celgene Corporation in a research report on Monday, July 31st. Finally, Argus raised Celgene Corporation from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $96.93 to $160.00 in a research report on Monday, July 31st. One analyst has rated the stock with a sell rating, six have issued a hold rating, twenty-two have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $147.00.

In other news, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the sale, the insider now directly owns 4,004 shares of the company’s stock, valued at $481,200.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00. Following the completion of the sale, the director now directly owns 76,301 shares in the company, valued at $10,264,010.52. The disclosure for this sale can be found here. Insiders sold 235,255 shares of company stock worth $31,377,042 over the last ninety days. Insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.